Merck & (MRK) Revenue — Quarter Ended Dec 31, 2024
Revenue for the reported quarter declined compared to the immediately preceding quarter but rose relative to the same quarter one year earlier. The company's filing context notes stronger full-year operating performance.
Key takeaway
Quarter ended Dec 31, 2024 · FY2024 Q4
Revenue for the reported quarter declined compared to the immediately preceding quarter but rose relative to the same quarter one year earlier. The company's filing context notes stronger full-year operating performance.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$15.6B
Revenue reported for this quarter.
Quarter-over-quarter
-6.2%
Change from the immediately preceding quarter.
Year-over-year
+6.8%
Change from the comparable year-ago quarter.
Trailing four quarters
$64.2B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2024 | $15.8B | +8.9% |
| Jun 30, 2024 | $16.1B | +7.2% |
| Sep 30, 2024 | $16.7B | +4.4% |
| Dec 31, 2024 | $15.6B | +6.8% |
Revenue performance
The reported revenue decreased sequentially, reflecting a downturn from the prior quarter. On a year-over-year basis, however, revenue increased.
Quarterly comparison
The sequential decline contrasts with the year-over-year gain, indicating a mixed quarterly performance. The trailing twelve-month revenue remained at a high level.
What to watch
The company's operating cash flow improved significantly for the full year, which may warrant attention in upcoming periods.